Schott Pharma commits $371 million to new U.S. manufacturing facility for GLP-1, mRNA therapies

Pharma packaging company Schott Pharma has unveiled plans to establish a new manufacturing facility in Wilson, North Carolina. Schott Pharma says the $371 million investment in the U.S. facility will create more than 400 jobs in the region and significantly expand the company’s presence in the U.S., an increasingly important strategic market for the German company.

Schott also announced an expansion of its Müllheim manufacturing plant in February, which is shown on our map of 2024 facility openings and expansions.

Polymer syringe production a focus

The new site will be the first in the U.S. to manufacture prefillable polymer syringes, which are stored under deep-cold storage in the case of mRNA medications. It will also produce glass prefillable syringes for GLP-1 therapies used to treat diabetes and obesity. The company expects the facility to triple Schott Pharma’s contribution of glass and polymer syringes to the U.S. market by 2030.

Schott P…
Read more
  • 0

Two continents, two milestones: Schott Pharma’s American commitment and European stock market debut

Drug containment company Schott Pharma recently celebrated major milestones related to its longstanding U.S. presence and high-profile stock market debut in Germany. The company, a division of specialty glass manufacturer Schott AG based in Mainz, Germany, commemorated 60 years of operations in the U.S. in August. Its primary American facility located in Lebanon County, Pennsylvania has played a role in providing drug containment for the U.S. pharmaceutical market. The company also offers drug delivery products.

Schott Pharma goes public

In parallel, Schott Pharma successfully launched its initial public offering on the Frankfurt Stock Exchange in late September, debuting at €30 per share and valuing the company at up to €4.1 billion. The offering was a strategic move to access capital markets and match competitors’ capabilities. Schott Pharma reported sales growth of 8.4% year-over-year for the first nine months of 2023, reaching €670 million.

With a portfolio…

Read more
  • 0

8 drug delivery innovations you should know

Innovations in drug delivery never stop and, over the past 12 months or so, a wide variety have come under the spotlight.

Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing just how many ways we can deliver therapeutics.

About a year ago, we clued in readers to a list of six drug delivery innovations they should know. Here, we provide a couple of updates on those and try to introduce a few more developments that you should know:

The latest in automated insulin delivery tech

Automated insulin delivery represents one of the most high-profile markets in drug delivery, with the technology providing potentially life-saving therapy for people with diabetes.

The Mobi automated insulin pump with the accompanying mobile app. [Image courtesy of Tandem Diabetes Care]Last year’s roundup included the already FDA-cleared Omn…
Read more
  • 0

Schott Pharma launches pre-filled polymer syringes for deep-cold drugs

The Toppac Freeze pre-filled syringe. [Image courtesy of Schott Pharma]Schott Pharma announced today that it launched pre-fillable syringes made from advanced polymers for delivering deep-cold drugs.

These deep-cold drugs are stored and transported on dry ice at temperatures reaching -100°C. Schott designed the syringes from an advanced, pharmaceutical-grade polymer, delivered in a standardized nest and tub configuration. This ensures compatibility on major fill-finish lines to simplify the filling process.

Drug manufacturers can benefit from an extensive scientific data package developed by Schott. It details the 1 mL-long syringes’ performance at deep-cold temperatures. These syringes also raise the bar on quality, Schott said, with best-in-class specification and a fast-track supply process.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0